-
Biosimilar Pipeline Analysis Market Detailed in New Research Report By 2032 | Biocon, Pfizer Inc, Merck & Co.
06 Feb 2025 14:30 GMT
… and Factors updated research methodology
𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝
Biocon, Pfizer Inc., F. Hoffmann-La … Spectrometry
❖ Western Blotting
By Application:
❖ Oncology Disease
❖ Auto immune Disease
❖ Blood …
-
Biocon Biologics sees diversified global expansion offsetting US localisation risks
01 Feb 2025 08:00 GMT
… -Nordics clusters, he noted. Additionally, Biocon Biologics is experiencing positive traction … aligned.”
Quarter performance for Biologics
Biocon Biologics reported ₹2,289 crore … cent of total revenue.
The oncology franchise witnessed a significant increase …
-
Biocon raises stake in Biocon Biologics to 90.2% with Rs 5,550 crore acquisition
31 Jan 2025 21:15 GMT
… of its material subsidiary, Biocon Biologics Limited (BBL), from … . Following this transaction, Biocon’s total stake in …
This acquisition aligns with Biocon’s long-term strategy … therapeutic areas such as diabetology, oncology, immunology, and ophthalmology. …
-
India’s Biocon plans IPO for biosimilars business by March 2026
31 Jan 2025 15:50 GMT
… (Reuters) – Indian biopharmaceutical firm Biocon is likely to list its … market share for them, Biocon Biologics CEO Shreehas Tambe … therapy areas including diabetes, oncology and immunotherapy.
The company’ … 40% in revenue to Biocon Biologics, followed by 35% …
-
Biocon Biologics sees insulin demand growing across markets, says CEO Tambe
31 Jan 2025 14:02 GMT
… Europe.
Also Read | Biocon Biologics integrates Vitaris’ biosimilars … market share for its oncology biosimilars grew significantly—Trastuzumab … comment on it.
Biocon Biologics has earlier raised … ; Tambe said.
The Biocon Group reported Q3FY25 operating …
-
Biosimilars Market is projected to reach $143.6 billion by 2031 | Amgen Inc., Biocon Ltd, Kashiv Bio Sciences
28 Jan 2025 08:25 GMT
PORTLAND, IA, UNITED STATES, January 28, 2025 /EINPresswire.com/ -- According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% …
-
Eicher Motors, Tata Consumer, Biocon & Chambal Fertilisers: 4 stock picks by SMC Global
27 Jan 2025 05:09 GMT
… Tata Consumer Products Ltd, Biocon Ltd and Chambal Fertilisers … in immunotherapy under development. Biocon remains focused on consolidating … of products in areas like oncology, diabetes, and immunology, … due to pricing pressures, Biocon expects growth from new …
-
Saudi Arabia Pharmaceutical Drugs Market Is Booming Worldwide 2025-2032: Julphar, Biocon Limited, BeiGene, Pfizer Inc.
23 Jan 2025 09:24 GMT
… PLC
◘ Jamjoom Pharmaceuticals Co.
◘ Julphar
◘ Biocon Limited
◘ BeiGene
This Report includes … ) Drugs
By Application: Cardiovascular, Musculoskeletal, Oncology, Anti-infective, Metabolic Disorder, Central …
-
Biocon Biologics to present at the 43rd annual J P Morgan Healthcare Conference
10 Jan 2025 11:09 GMT
… company and subsidiary of Biocon will present at the … top global therapeutic areas including oncology, immunology, diabetes, bone health … CEO & managing director, Biocon Biologics Ltd, said: “This … an exciting milestone for Biocon Biologics as we celebrate …
-
Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com
10 Dec 2024 14:58 GMT
…
Others
Therapeutic Area
Oncological Disorders
Autoimmune and … different therapeutic areas, including oncological disorders, autoimmune and … Report include:
Amgen
BIOCAD
Biocon
Celltrion
Coherus BioSciences
Reddy … REST OF THE WORLD
Biocon
Dr. Reddy…